ArticleDiabetology & metabolic syndrome2016

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.

Teruo Jojima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.